Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases

Last updated: March 16, 2026
Sponsor: University Hospital, Toulouse
Overall Status: Active - Recruiting

Phase

N/A

Condition

Connective Tissue Diseases

Rash

Dermatitis, Atopic

Treatment

Blood sampling

Remainders of samples taken as part of the treatment

Clinical Study ID

NCT06387654
RC31/23/0361
  • Ages 6-99
  • All Genders

Study Summary

The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Skin damage of documented or probable autoimmune, dysimmune or autoinflammatory origin.

The patients included may be adults or children, and will be:

  • Patients with autoimmune bullous dermatoses (pemphigus, pemphigoid and others),

  • Patients with systemic autoimmune diseases associated with skin damage (lupus,scleroderma, dermatomyositis for example),

  • Patients with cutaneous lupus

  • Patients with dysimmune skin diseases (psoriasis, eczema)

  • Patients with immuno-induced dermatological disorders or drug dermatitis

  • Patients receiving, or likely to receive, new, innovative therapies (new molecule onthe market, checkpoint inhibitors, gene therapy, cell therapy, etc.).

Patients with dermatological damage whose autoimmune, dysimmune or auto-inflammatory origin is suspected

Exclusion

Exclusion Criteria:

  • Patients under protective supervision (guardianship, curators)

  • Patients under 6 years old

  • Pregnant or breastfeeding woman

Study Design

Total Participants: 800
Treatment Group(s): 2
Primary Treatment: Blood sampling
Phase:
Study Start date:
May 06, 2024
Estimated Completion Date:
April 30, 2034

Study Description

Autoimmune diseases include around a hundred different clinical entities which are for the most part rare pathologies but which, in combination, concern 5-8% of the adult population with a strong female predominance (FAI²R: the disease chain rare autoimmune and auto-inflammatory drugs, fai2r.org). The common denominator of all these diseases is based on the breakdown of self-tolerance which is the origin of self-reactivity and whose physiopathological mechanisms are still not fully understood, which generates numerous cross-sectional or fundamental studies. In addition to this complexity, there are significant inter-individual variabilities which lead to the definition of subgroups of patients on the basis of the clinical-biological profile and / or the response to treatments. Consequently, and in view of the need to establish the diagnosis early and then to propose the best treatment in the perspective of an individualized medicine, the clinical, biological and genetic characteristics of these subgroups of patients must be explored in order to improve diagnostic and therapeutic capacities.

Connect with a study center

  • Purpan University Hospital

    Toulouse, 31059
    France

    Site Not Available

  • University Hospital

    Toulouse, 31059
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.